Biotech Research
Filter News
Found 1,561 articles
-
Through their work, they were able to determine that the protein, TAp63, appears to impact the level of RNA molecules within the body. This subsequently connects the activities of p53 and AKT, the altered genes in cancer.
-
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials
10/20/2020
Combination of over $50 million in committed capital along with access to cancer expertise and clinical facilities will help advance novel IND-ready candidates
-
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
10/19/2020
New preclinical study finds boosting NAD+ with nicotinamide riboside alleviated telomere damage, providing protective effect to DNA strands
-
8-Year-old Boy to Thank Donor He’s Never Met for Saving His Life During City of Hope’s 44th Bone Marrow Transplant Reunion, a Virtual Event
10/15/2020
It is understandably difficult for Ashley Montañez to talk about the moment a doctor told her Joseph, her only son, a kindergartner and 6 years old at the time, had cancer.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
New Brief: Counterfeit Drugs Harm Patients, Economy, Innovation; Drug Importation or Price Controls Would Make Problem Worse
10/13/2020
A new brief released by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm's way, hinder drug innovation, and lead to job losses.
-
National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy
10/13/2020
Lenzilumab among the promising agents selected for ACTIV program from pool of approximately 400 candidate agents
-
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
10/7/2020
Companies to broaden their existing partnership on Age-related Macular Degeneration (AMD) treatments OliX grants Théa worldwide rights excluding Asia-Pacific on OLX301A and OLX301D, targeting dry/wet AMD and wet AMD/subretinal fibrosis, respectively OliX further grants Théa option to nominate two additional ophthalmic programs Théa to invest €8.8 million through upfront payment for two AMD programs and an option fee for two additional ophthalmic programs SUWON, Republic of Korea and CLERMON
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
-
City of Hope launches AccessHope™, a wholly owned subsidiary dedicated to providing a first-of-its-kind, innovative cancer support model for employers to improve care, experience, outcomes and value
10/6/2020
AccessHope TM remotely connects patients to expertise from world-renowned national comprehensive cancer center, providing unparalleled decision support to patients and their treating physicians.
-
The Pershing Square Sohn Cancer Research Alliance Is Now Accepting Applications for its 2021 Prize for Early-Career, Radically Innovative Cancer Researchers
10/5/2020
The Pershing Square Sohn Cancer Research Alliance announced the opening of applications for its 2021 Prize for Young Investigators in Cancer Research.
-
NIH Awards $13.8 Million for Studies on the Prevention and Treatment of Alzheimer's Disease
10/5/2020
Joe Verghese, M.B.B.S., M.S., an international leader in aging and cognition research at Albert Einstein College of Medicine and Montefiore Health System, has received two grants from the National Institutes of Health totaling $13.8 million to conduct studies on pre-dementia and Alzheimer's disease.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Matrix Medical Network to Support COVID-19 Vaccine Trials as Part of Operation Warp Speed
10/1/2020
Matrix Medical Network ® (Matrix) will be a key enabler in clinical trials of investigational COVID-19 vaccines conducted by the COVID-19 Prevention Network. Matrix Clinical Solutions, through an agre
-
Feinstein Researchers Develop New Method to Observe Vagal Fibers Activation During Vagus Nerve Stimulation
10/1/2020
Researchers at The Feinstein Institutes for Medical Research have developed a way to observe the effects of vagus nerve stimulation (VNS) – the act of electrically stimulating one of the body’s main nerves – by non-invasively measuring bodily responses, including neck muscle activity, heart rate (HR) and breathing. After validation, this methodology could be used in humans. This press release features multimedia. Vie
-
City of Hope-led study details new strategy to address the barriers that keep older adults out of clinical trials
10/1/2020
The study examined what has been done and chartered a roadmap to improve equitable access using the best-available scientific literature on barriers to older adult participation in cancer clinical trials.
-
VoxNeuro and UHN Sign Agreement to Launch Concussion Study
10/1/2020
UHN will utilize VoxNeuro’s neurotechnology to generate objective quantifiable data to study the improvement in all core brain functions
-
City of Hope Distinguished Scientist Debbie Thurmond Named New Director of Diabetes & Metabolism Research Institute
9/30/2020
Leading diabetes scientist Debbie C. Thurmond, Ph.D., has been named the new director of City of Hope’s Diabetes & Metabolism Research Institute, which continues diabetes research at City of Hope that was started more than 70 years ago.
-
South Rampart Pharma Receives $1.9 Million NIH Fast-Track STTR Commercialization Grant to Advance its New Class of Non-Opioid Pain Medicines
9/29/2020
South Rampart Pharma, a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines, has been awarded a $1.9 million Small Business Technology Transfer grant by the National Institutes of Health.
-
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
9/29/2020
Aptorum Group Limited announced its launch of Aptorum Innovations - an infectious disease liquid biopsy diagnostics subsidiary and its newly established exclusive in-licensing arrangements with Accelerate Technologies Pte Ltd